Tysabri Risk Plan Could Be Implemented In Weeks, Biogen Predicts
Biogen Idec expects to implement its risk management plan for multiple sclerosis therapy Tysabri in a matter of weeks following the product's return to market, the company said one day after the FDA advisory committee meeting on the product
You may also be interested in...
Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials